Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law.
Drug manufacturer litigation against the Inflation Reduction Act (IRA) drug pricing-negotiation program continues, with the US Supreme Court currently weighing whether to grant certiorari.
